Plasma prednisolone studies in rheumatic patients

Area of Science:

• Pharmacology
• Rheumatology
• Clinical Medicine

Background:

• Glucocorticoids like prednisolone are mainstays in rheumatic disease management.
• Understanding plasma drug concentration is key to optimizing therapy.
• Individual variability in drug absorption and metabolism poses challenges.

Purpose of the Study:

• To investigate plasma prednisolone concentrations in patients with rheumatic diseases on maintenance therapy.
• To explore the relationship between prednisolone levels, dosage, disease activity, and cortisol suppression.
• To evaluate the concept of an optimal therapeutic range for plasma prednisolone.

Main Methods:

• Plasma prednisolone levels were monitored in 83 rheumatic disease patients receiving daily maintenance doses.
• Standard and enteric-coated prednisolone preparations were assessed.
• Drug levels were correlated with dose, disease activity, and basal cortisol production.

Main Results:

• Plasma prednisolone levels peaked at 1 hour with standard tablets; enteric-coated absorption was unpredictable.
• Significant inter-individual variation in plasma prednisolone concentrations was observed.
• No consistent relationship was found between drug levels (total or unbound) and prednisolone dose or disease control.
• Basal cortisol production was suppressed in one-third of patients.

Conclusions:

• Plasma prednisolone pharmacokinetics exhibit considerable inter-individual variability in rheumatic disease patients.
• The study does not support the existence of an 'optimum therapeutic range' for plasma prednisolone in this population.
• Clinical monitoring should account for this variability rather than relying on fixed plasma concentration targets.